PHASERX, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0002 USD | -.--% |
|
-.--% | -.--% |
| 2019 | Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc. | CI |
| 2018 | PhaseRx, Inc. Bankruptcy Case Dismissed | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2015 | 375K | Sales 2016 | - | Capitalization | 18.12M |
|---|---|---|---|---|---|
| Net income 2015 | -7M | Net income 2016 | -20M | EV / Sales 2015 * | - |
| Net Debt 2015 | 16.55M | Net cash position 2016 | 9.78M | EV / Sales 2016 | - |
| P/E ratio 2015 * |
-
| P/E ratio 2016 |
-0.58
x | Employees | 10 |
| Yield 2015 * |
-
| Yield 2016 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
1 year
0.00
0.00
3 years
0.000.10
5 years
0.000.10
10 years
0.005.77
Pz Wind Down, Inc., formerly, PhaseRx, Inc. is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The Company's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 2.34K | |
| +8.28% | 115B | |
| +13.12% | 107B | |
| -12.61% | 22.31B | |
| -3.99% | 21.6B | |
| -7.07% | 18.23B | |
| -39.93% | 17.62B | |
| +6.58% | 14.26B | |
| +33.75% | 12.37B | |
| -29.11% | 8.28B |
- Stock Market
- Equities
- PZRXQ Stock